SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    World Health Organization. (2008) Drug resistant tuberculosis in the South-East Asia region Status Report. New Delhi: Regional Office for South-East Asia, pp. 19.
  • 2
    World Health Organization. TB in South- East Asia, Epidemiology of TB in the Region. 1 December 2011. Available from: http://www.searo.who.int/en/Section10/Section2097/Section2100_14803.htm
  • 3
    Jittimanee S., Vorasingha J., Mad-asin W., Nateniyom S., Rienthong S., Varma J.K. (2009) Tuberculosis in Thailand: epidemiology and program performance, 2001–2005. Int J Infect Dis 13: 43642.
  • 4
    Anyama N., Sseguya S., Okwera A., A El-Naggar W., Mpagi F., Owino E. (2007) The challenge of retreatment pulmonary tuberculosis at two teaching and referral hospitals in Uganda. African Health Sciences 7(3): 13642.
  • 5
    Centers for Disease Control and Prevention. (2003) Update: Treatment of tuberculosis/CDC recommendations and reports. MMWR 52(RR-11): 180.
  • 6
    Canetti G., Sutherland I., Svandova E. (1972) Endogenous reactivation and exogenous reinfection: their relative importance with regard to the development of non-primary tuberculosis. Bull Int Union Tuberc 47: 11634.
  • 7
    Chaves F., Dronda F., Alonso-Sanz M., Noriega A.R. (1999) Evidence of exogenous reinfection and mixed infection with more than one strain of Mycobacterium tuberculosis among Spanish HIV-infected inmates. AIDS 13(5): 61520.
  • 8
    Bandera A., Gori A., Catozzil L., Degliesposti A., Marchetti G., Molteni C. (2001) Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. J Clin Microbiol 39(6): 22138.
  • 9
    Connolly C., Reidb A., Daviesb G., Sturmc W., McAdamd K.P., Wilkinsona D. (1999) Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS 13: 154347.
  • 10
    Yoshiyama T., Yanai H., Rhiengtong D., Palittapongarnpim P., Nampaisan O., Supawitkul S., Uthaivorawit W., Mori T. (2004) Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis 8(1): 3138.
  • 11
    van Embden J.D., Cave M.D., Crawford J.T., Dale J.W., Eisenach K.D., Gicquel B., Hermans P., Martin C., McAdam R., Shinnick T.M. (1993) Strain Identification of Mycobacterium tuberculosis by DNA fingerprinting: Recommendations for a standardized methodology. J Clin Microbiol 31(2): 4069.
  • 12
    McEvoy C.R., Falmer A.A., van Pittius N.C., Victor T.C., van Helden P.D., Warren R.M. (2007) .The role of IS6110 in the evolution of Mycobacterium tuberculosis. Tuberculosis 87: 393404.
  • 13
    Rienthong D., Ajawatanawong P., Rienthong S., Smithtikarn S., Akarasewi P., Chaipresert A., Palittapongarnpim P. (2005) Restriction fragment length polymorphism study of nationwide samples of Mycobacterium tuberculosis in Thailand, 1997–1998. Int J Tuberc Lung Dis 9(5): 57681.
  • 14
    Glynn J.R., Whiteley J., Bifani P.J., Kremer K., Soolingen V.D. (2002) Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: A systematic review. Emerg Infect Dis 8(8): 8439.
  • 15
    Lillebaek T. (2005) The molecular epidemiology of tuberculosis. Dan Med Bull 52: 14359.
  • 16
    Sun Y.J., Lim T.K., Yeow Ong A.K., Heng Ho B.C., Seah G.T., Paton N. (2006) Tuberculosis associated with Mycobacterium tuberculosis Beijing and non-Beijing genotypes: a clinical and immunological comparison. BMC Infect Dis 6: 105.
  • 17
    World Health Organization. WHO Library Cataloguing in Publication Data: Treatment of tuberculosis: guidelines fourth edition. WHO/HTM/TB/2009.420. Available from: http://www.who.int/tb/publications/tb_treatmentguidelines/en/index.html.
  • 18
    Glynn J.R., Yates M.D., Crampin A.C., Ngwira B.M., Mwaungulu F.D., Black G.F., Chaguluka S.D., Mwafulirwa D.T., Floyd S., Murphy C., Drobniewski F.A., Fine P.E. (2004) DNA fingerprint changes in tuberculosis: reinfection, evolution, or laboratory error? J Infect Dis 190: 115866.
  • 19
    van Soolingen D., de Haas P.E., Blumenthal R.M., Kremer K., Sluijter M., Pijnenburg J.E., Schouls L.M., Thole J.E., Dessens- Kroon M.W., van Embden J.D., Hermans P.W. (1996) Host-mediated modification of PvuII restriction in Mycobacterium tuberculosis. J Bacteriol 178(1): 7884.
  • 20
    Palittapongarnpim P., Luangsook P., Tansuphaswadikul S., Chuchottaworn C., Prachktam R., Sathapatayavongs B. (1997) Restriction fragment length polymorphism study of Mycobacterium tuberculosis in Thailand using IS6110 as probe. Int Tuberc Lung Dis 1(4): 3706.
  • 21
    Mazurek H.G., Cave M.D., Eisenach K.D., Wallace R.J., Bates J.H., Craford J.T. (1991) Chromosomal DNA fingerprint patterns produced with IS6110 as strain-spcific markers for epidemiologic study of tuberculosis. J Clin Microbiol 29(9): 20303.
  • 22
    World Health Organization. (2006) Guideline for the programmatic management of drug-resistant tuberculosis. Update 2011.
  • 23
    Nettles R.E., Mazo D., Alwood K., Gachuhi R., Maltas G., Wendel K., Cronin W., Hooper N., Bishai W., Sterling T.R. (2004) Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. HIV/AIDS CID 38(1): 7316.
  • 24
    Churchyard G.J., Corbett E.L., Kleinschmidt I., Mulder D., Cock D.K.M. (2003) Drug-resistant tuberculosis in South African gold miners: incidence and associated factors. Int J Tuberc Lung Dis 4(5): 43340.
  • 25
    Mitchison D.A. (1998) How resistance emerge as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 2: 105.
  • 26
    Kritski A.L., Rodrigues de Jesus L.S., Andrade M.K., Werneck- Barroso E., Vieira M.A., Hoffner A., Riley L.W. (1997) Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 111: 11627.
  • 27
    Verver S., Warren R.M., Beyers N., Richardson M., van der Spuy G.D., Borgdorff M.W., Enarson D.A., Behr M.A., van Helden P.D. (2005) Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 171(12): 143035.
  • 28
    Thong-On A., Smittipat N., Juthayothin T., Yanai H., Yamada  , Yorsangsukkamol J., Chaiprasert A., Rienthong D., Billamas P., Palittapongarnpim P. (2010) Variable-number tandem repeats typing of Mycobacterium tuberculosis isolates with low copy numbers of IS6110 in Thailand. Tuberculosis 90: 915.
  • 29
    Small P.M., Shafer R.W., Hopewell P.C., Singh S.P., Murphy M.J., Desmon E., Sierra M.F., Schoolnik G.K. (1993) Exogenous reinfection with multidrug resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 328: 113744.
  • 30
    van Rie A., Warren R., Richardson M., Victor T.C., Gie R.P., Enarson D.A., Bevers N., van Helden P.D. (1999) Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 341(16): 11749.
  • 31
    Shen G., Xue Z., Shen X., Sun B., Gui X., Shen M., Mei J., Gao Q. (2006) Recurrent tuberculosis and exogenous reinfection, Shanghai, China. Emerg Infect Dis 12(11): 17768.
  • 32
    Chiang C.Y., Riley L.W. (2005) Exogenous reinfection in tuberculosis. Lancet Infect Dis 5: 62936.
  • 33
    Kobinica T., Rusch- Gerdes S., Niemann S. (2004) The Beijing genotype is emerging among multidrug-resistant Mycobacterium tuberculosis strains from Germany. Int Tuberc Lung Dis 8(9): 110713.
  • 34
    Faksri K., Drobniewski F., Nikolayevskyy V, Brown T., Prammananan T., Palittapongarnpim P., Prayoonwiwat N., Chaiprasert A. (2011) Genetic diversity of the Mycobacterium tuberculosis Beijing family based on IS6110, SNP, LSP and VNTR profiles from Thailand. Infection, Genetics and Evolution 11: 114249.